News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1โ€“36
Matches
253
Sources here
1
Companies here
1
Search results Stored financial headlines

Active search

253 matching headlines

Ticker or company: LLYMain companies and provider mentions
Clear
Latest

finance.yahoo.com Earnings

Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Eli Lilly (LLY), which belongs to the Zacks Large Cap Pharmaceuticals industry, could be a great candidate to consider. When looking at the last two reports, this drugmaker has recorded a strong โ€ฆ

Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina
Read at finance.yahoo.com
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
Just inNext headlines
finance.yahoo.com Earnings Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease

In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo Combined with recent research on the savings tied to weight loss, these findings suggest Foundayo could โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Analyst action Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly Weight-Loss Drug Foundayo Meets Primary Endpoint in Phase 3 Trial

Eli Lilly's (LLY) weight-loss drug, Foundayo, has met the primary endpoint in a phase 3 trial of adu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Earnings Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-planned analyses, Foundayo showed a 53% lower risk of cardiovascular death and a 57% โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly (LLY) Suffers a Larger Drop Than the General Market: Key Insights

Eli Lilly (LLY) closed at $1,157.08 in the latest trading session, marking a -2.33% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.25%. At the same time, the Dow lost 0.86%, and the tech-heavy Nasdaq โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes

Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% compared to 2.4% with tirzepatide 15 mg Based on results โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis

EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA 0/1) by Week 16, with significant skin clearance as early as one month EBGLYSS delivered significant itch and pain relief, โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly Shares Rise After Foundayo Shows More Weight Loss

This article first appeared on GuruFocus. Eli Lilly (LLY) edged 1% higher in morning Tuesday trading after new data pointed to greater weight and blood-sugar reductions from its oral Foundayo treatment than oral semaglutide at higher doses. The analysis examined 17.2 mg of Foundayo, โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison

In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity Participants receiving Zepbound 15 mg had more than three times the odds of achieving at least 20% body-weight reduction compared with Wegovy HD INDIANAPOLIS, Sept. โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Deals and strategy Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

What Could Eli Lilly (LLY) New Cancer Win And Deal Shift Mean?

Eli Lilly (NYSE:LLY) received FDA Breakthrough Therapy designation for its next-generation KRAS G12C inhibitor olomorasib in advanced pancreatic cancer. The pharmaceutical group launched a global Change the Course program aimed at broadening access to its diabetes and obesity treatments in low and middle income โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison

Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks These additional analyses build on findings of the ACHIEVE-3 head-to-head study, where Foundayo 9 mg and 17.2 mg delivered greater A1C โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly and Company (LLY) is Expanding Beyond its Biggest Growth Drivers. Can it Sustain the Momentum?

On September 25, Eli Lilly and Company (NYSE:LLY) announced that the U.S. FDA approved Olumiant (baricitinib), a once-daily pill, for pediatric patients 12 years of age and older with severe alopecia areata (AA). The decision expands Olumiant's label beyond established adult indications in moderately โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market's view of the two companies has changed sharply. Since mid-2024, Novo's stock has fallen roughly 74%, while Lilly's has โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly (LLY) Wins Two FDA Approvals And A $3.35 Billion Drug Alliance

Eli Lilly (NYSE:LLY) received FDA approval for Olumiant to treat pediatric patients with severe alopecia areata. The FDA also cleared once weekly insulin Onswik for adults with type 2 diabetes, adding a new dosing option. Eli Lilly agreed a global drug discovery alliance with โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Regulatory and legal Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds

A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co.(NYSE:LLY) breached the implied covenant of good faith and fair dealing. Nektar Therapeutics Wins $90 Million Judgment Against Eli Lilly The lawsuit, filed in โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly (LLY) Stock Is Up, What You Need To Know

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, giving patients an alternative to daily long-acting insulin โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly Jumps 3.64% While a $100 Billion Obesity Race Crowds In

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the obesity and diabetes drugmaker, faces a growing field of challengers chasing a weight loss market that could reach $100 billion in annual sales. Shares rose about 3.6% to $1,192.91 at 10.51am ET Time on โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Balance sheet Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly Slips as $6.5 Billion Plant Backs Oral GLP-1 Scale

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the obesity and diabetes drugmaker, broke ground on a $6.5 billion Houston plant built to make ingredients for its Foundayo weight-loss pill and other medicines. Shares slipped about 0.8% to $1,160.91 Wednesday morning. That puts โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year

Quick Read Lilly's incretin franchise hit ~$15B in a single quarter while LLY shares surged 56% over the past year, leaving PFE trading at just 9x forward earnings with a 6.22% yield. Retatrutide's BLA filing in Q1 2027 across obesity, sleep apnea, and osteoarthritis โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week'

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Eli Lilly and Co.'s CEO Dave Ricks announced a significant increase in the use of GLP-1 treatments among seniors, following Medicare's July decision to cover obesity drugs. โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly Rises Higher as Viking Preserves Up to 90% Monthly

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the obesity-and-diabetes drug leader, confronted a fresh competitive wrinkle after Viking Therapeutics released maintenance-dosing results for VK2735. Lilly shares rise 0.8% higher at $1,174.37 Tuesday. Is LLY fairly valued? Test your thesis with our free โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Should Eli Lilly (LLY) Investors Watch Its $6.5 Billion Houston GLP 1 Buildout?

Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug Foundayo. The new site is focused on supplying Foundayo for obesity treatment as demand for oral GLP-1 therapies grows in the US and abroad. โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Beyond Eli Lilly and Novo Nordisk: Rising Obesity Drug Stocks to Watch

Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordiskโ€™s market duopoly. Continue Reading

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly CEO Delivers Urgent Message on the Company's Next Big Weight-Loss Pill

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) is expanding manufacturing capacity for its new oral obesity treatment as Chief Executive David Ricks said the drug is gaining ground among patients starting GLP-1 pills. Ricks told CNBC that Foundayo accounts for roughly one-third โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Macro sensitivity Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly Just Got a Big Boost From Medicare's GLP-1 Expansion

This article first appeared on GuruFocus. Eli Lilly (LLY, Financials), is gaining an early edge as expanded Medicare coverage brings more seniors into the fast-growing market for GLP-1 obesity treatments. Warning! GuruFocus has detected 3 Warning Sign with PSKY. Is LLY fairly valued? Test โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lillyโ€™s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon

Quick Read Citigroup's Geoff Meacham targets $1,600 for LLY, representing 37% upside, anchored by Mounjaro and Zepbound's combined $14.9B single-quarter revenue. Novo Nordisk dropped 8% in one session after its post-Wegovy update disappointed, while Viking Therapeutics carries 207% implied upside on clinical-stage binary risk. โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly (LLY) Increases Yet Falls Behind Market: What Investors Need to Know

Eli Lilly (LLY) closed the most recent trading day at $1,164.89, moving +1.04% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.49%. Elsewhere, the Dow gained 0.71%, while the tech-heavy Nasdaq added 2.26%. Shares of โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020

New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chain Site will employ more than 600 people in high-wage jobs $12.5 million in support to build talent pipeline, workforce training center with San Jacinto College HOUSTON, Sept. 21, โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly Gains as Novo Wins a Lower-Dose Weight-Loss Round

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the obesity-and-diabetes medicine leader, faced a fresh competitive data point Monday after Novo Nordisk (NYSE:NVO) said CagriSema beat tirzepatide's 5-milligram dose in a late-stage diabetes study. Lilly shares still climbed about 1.2% to $1,166.74, suggesting โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

The Next Chapter of Eli Lilly Could Be Bigger Than Investors Expect

Quick Read LLY posts 48% revenue growth with Mounjaro and Zepbound generating $14.9B in Q2, yet shares are up only 8% year to date. Reaching $1,500 by end of 2027 requires just 30% upside and a 39x forward P/E, only modestly above the current โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Lilly CEO Dave Ricks says Foundayo winning new pill patients

Eli Lilly CEO Dave Ricks said Monday that Foundayo now accounts for one in three new oral weight loss drug starts in the United States, with the pill capturing a larger slice of that market each week. Dave Ricks made the remarks in an โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly (LLY) Could Be 22% Undervalued On New Breast Cancer Approval

Eli Lilly (LLY) is back in focus after the U.S. Food and Drug Administration granted full approval for Inluriyo, used with Verzenio in certain ESR1 mutated metastatic breast cancer patients. Eli Lilly's share price has eased over the past month, with a 30-day share โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Eli Lilly (LLY) Stock Fair Value Edges Higher As Analysts Back GLP 1 Growth

Eli Lilly's updated fair value estimate has shifted from US$1,297.31 to US$1,325.39, adding a fresh data point to an already closely watched price target range. This move sits alongside analyst price targets that often sit above US$900, with a cluster between US$1,300 and US$1,600, โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

What Would It Take For Eli Lilly Stock To Keep Climbing?

Image from Pixabay Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

Can Eli Lillyโ€™s Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?

Quick Read Eli Lilly presents mid-stage eloraTZP data September 30, and LLY stock near $1,152 with a $1 trillion market cap leaves no room for a weak result. Novo Nordisk's GLP-1 franchise faces headwinds while Viking Therapeutics' VK2735 looms; a convincing eloraTZP win raises โ€ฆ

LLY mentioned
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026
finance.yahoo.com Deals and strategy Main company ๐Ÿ‡ฆ๐Ÿ‡ท Argentina

What Does Eli Lilly (LLY) Gain From Its New Genetic Medicine Partnership?

Eli Lilly (NYSE:LLY) has entered an exclusive research collaboration with QurCan Therapeutics to develop genetic medicines for nervous system diseases. The agreement centers on QurCan's polymer lipid nanoparticle delivery platform for central and peripheral nervous system targets, with Eli Lilly responsible for later development โ€ฆ

LLY main company
Sharemaestro market context Trend signal active 52 weeks +50.0% LLY stored weekly price path from 3 Oct 2025 to 25 Sep 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context